# 374Water Inc.: financial statements, quarterly

SCWO · Nasdaq · CIK 933972 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/scwo.md) · [Financials](/companies/scwo/financials.md) · [Filings](/companies/scwo/filings.md) · [Insiders](/companies/scwo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/scwo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [12.3](/filings/0001654954-24-014442.md) | [(120) d](/filings/0001654954-25-003443.md) | [315](/filings/0001654954-25-005746.md) | [36.8](/filings/0001654954-25-009437.md) | [81.5](/filings/0001654954-25-012910.md) | [11.9 d](/filings/0001654954-26-003094.md) | [543](/filings/0001654954-26-004903.md) | [595](/filings/0001654954-26-007650.md) | [760](/filings/0001654954-25-012910.md) | [(1,683) d](/filings/0001654954-26-003094.md) | [551](/filings/0001654954-26-004903.md) | [2,262](/filings/0001654954-26-007650.md) |
| Cost of revenue | $k | [179](/filings/0001654954-24-014442.md) | [908 d](/filings/0001654954-24-003957.md) | [617](/filings/0001654954-25-005746.md) | [43.5](/filings/0001654954-25-009437.md) | [42.4](/filings/0001654954-25-012910.md) | [655 d](/filings/0001654954-26-003094.md) | [405](/filings/0001654954-26-004903.md) | [871](/filings/0001654954-26-007650.md) | [548](/filings/0001654954-25-012910.md) | [742 d](/filings/0001654954-26-003094.md) | [203](/filings/0001654954-26-004903.md) | [279](/filings/0001654954-26-007650.md) |
| Gross profit | $k | [(166)](/filings/0001654954-24-014442.md) | [(1,028) d](/filings/0001654954-25-003443.md) | [(302)](/filings/0001654954-25-005746.md) | [(6.7)](/filings/0001654954-25-009437.md) | [39.1](/filings/0001654954-25-012910.md) | [(643) d](/filings/0001654954-26-003094.md) | [138](/filings/0001654954-26-004903.md) | [(276)](/filings/0001654954-26-007650.md) | [213](/filings/0001654954-25-012910.md) | [(2,426) d](/filings/0001654954-26-003094.md) | [348](/filings/0001654954-26-004903.md) | [1,983](/filings/0001654954-26-007650.md) |
| Research and development | $k | [318](/filings/0001654954-24-014442.md) | [551 d](/filings/0001654954-25-003443.md) | [535](/filings/0001654954-25-005746.md) | [567](/filings/0001654954-25-009437.md) | [425](/filings/0001654954-25-012910.md) | [617 d](/filings/0001654954-26-003094.md) | [534](/filings/0001654954-26-004903.md) | [531](/filings/0001654954-26-007650.md) | [756](/filings/0001654954-25-012910.md) | [704 d](/filings/0001654954-26-003094.md) | [450](/filings/0001654954-26-004903.md) | [285](/filings/0001654954-26-007650.md) |
| Operating income | $k | [(1,882)](/filings/0001654954-24-014442.md) | [(3,313) d](/filings/0001654954-25-003443.md) | [(2,201)](/filings/0001654954-25-005746.md) | [(3,019)](/filings/0001654954-25-009437.md) | [(2,742)](/filings/0001654954-25-012910.md) | [(4,841) d](/filings/0001654954-26-003094.md) | [(3,786)](/filings/0001654954-26-004903.md) | [(4,638)](/filings/0001654954-26-007650.md) | [(4,361)](/filings/0001654954-25-012910.md) | [(8,363) d](/filings/0001654954-26-003094.md) | [(4,598)](/filings/0001654954-26-004903.md) | [(1,622)](/filings/0001654954-26-007650.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001654954-24-014442.md) | [0.0 d](/filings/0001654954-25-003443.md) | [0.0](/filings/0001654954-25-005746.md) | [0.0](/filings/0001654954-25-009437.md) | [0.0](/filings/0001654954-25-012910.md) | [0.0 d](/filings/0001654954-26-003094.md) | [0.0](/filings/0001654954-26-004903.md) | [0.0](/filings/0001654954-26-007650.md) | [0.0](/filings/0001654954-25-012910.md) | [0.0 d](/filings/0001654954-26-003094.md) | [0.0](/filings/0001654954-26-004903.md) | [0.0](/filings/0001654954-26-007650.md) |
| Net income | $k | [(1,731)](/filings/0001654954-24-014442.md) | [(3,081) d](/filings/0001654954-25-003443.md) | [(2,024)](/filings/0001654954-25-012910.md) | [(2,932)](/filings/0001654954-25-012910.md) | [(2,702)](/filings/0001654954-25-012910.md) | [(4,776) d](/filings/0001654954-26-003094.md) | [(3,698)](/filings/0001654954-26-007650.md) | [(4,580)](/filings/0001654954-26-007650.md) | [(4,349)](/filings/0001654954-25-012910.md) | [(8,347) d](/filings/0001654954-26-003094.md) | [(4,572)](/filings/0001654954-26-007650.md) | [(2,696)](/filings/0001654954-26-007650.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.02)](/filings/0001654954-25-005746.md) | [(0.02)](/filings/0001654954-25-009437.md) | [0.02](/filings/0001654954-25-012910.md) | not reported | [(0.26)](/filings/0001654954-26-004903.md) | [0.32](/filings/0001654954-26-007650.md) | [0.03](/filings/0001654954-25-012910.md) | not reported | [(0.26)](/filings/0001654954-26-004903.md) | [0.15](/filings/0001654954-26-007650.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [12.8](/filings/0001654954-23-014032.md) | [10.4](/filings/0001654954-25-003443.md) | [7.9](/filings/0001654954-24-006425.md) | [5.1](/filings/0001654954-24-010673.md) | [2.0](/filings/0001654954-24-014442.md) | [10.7](/filings/0001654954-25-003443.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [16.8](/filings/0001654954-23-014032.md) | [14.9](/filings/0001654954-25-003443.md) | [13.3](/filings/0001654954-24-006425.md) | [8.8](/filings/0001654954-24-010673.md) | [6.1](/filings/0001654954-24-014442.md) | [14.9](/filings/0001654954-26-003094.md) | [11.6](/filings/0001654954-25-005746.md) | [7.5](/filings/0001654954-25-009437.md) | [6.2](/filings/0001654954-25-012910.md) | [5.9](/filings/0001654954-26-007650.md) | [5.2](/filings/0001654954-26-004903.md) | [6.0](/filings/0001654954-26-007650.md) |
| Total assets | $m | [18.0](/filings/0001654954-23-014032.md) | [16.1](/filings/0001654954-25-003443.md) | [14.5](/filings/0001654954-24-006425.md) | [12.2](/filings/0001654954-24-010673.md) | [10.1](/filings/0001654954-24-014442.md) | [19.2](/filings/0001654954-26-003094.md) | [16.0](/filings/0001654954-25-005746.md) | [12.4](/filings/0001654954-25-009437.md) | [11.4](/filings/0001654954-25-012910.md) | [11.4](/filings/0001654954-26-007650.md) | [11.0](/filings/0001654954-26-004903.md) | [13.0](/filings/0001654954-26-007650.md) |
| Current liabilities | $m | [0.6](/filings/0001654954-23-014032.md) | [1.4](/filings/0001654954-25-003443.md) | [1.6](/filings/0001654954-24-006425.md) | [1.5](/filings/0001654954-24-010673.md) | [1.6](/filings/0001654954-24-014442.md) | [3.1](/filings/0001654954-26-003094.md) | [2.8](/filings/0001654954-25-005746.md) | [2.9](/filings/0001654954-25-009437.md) | [4.3](/filings/0001654954-25-012910.md) | [4.2](/filings/0001654954-26-007650.md) | [3.6](/filings/0001654954-26-004903.md) | [3.6](/filings/0001654954-26-007650.md) |
| Total liabilities | $m | [0.6](/filings/0001654954-23-014032.md) | [1.4](/filings/0001654954-25-003443.md) | [1.6](/filings/0001654954-24-006425.md) | [1.5](/filings/0001654954-24-010673.md) | not reported | [3.7](/filings/0001654954-26-003094.md) | [3.4](/filings/0001654954-25-005746.md) | [3.4](/filings/0001654954-25-009437.md) | [4.9](/filings/0001654954-25-012910.md) | [4.7](/filings/0001654954-26-007650.md) | [7.3](/filings/0001654954-26-004903.md) | [10.0](/filings/0001654954-26-007650.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [17.5](/filings/0001654954-24-014442.md) | [14.7](/filings/0001654954-26-003094.md) | [12.9](/filings/0001654954-25-012910.md) | [10.7](/filings/0001654954-25-012910.md) | [8.5](/filings/0001654954-25-012910.md) | [15.5](/filings/0001654954-26-007650.md) | [12.6](/filings/0001654954-26-007650.md) | [8.9](/filings/0001654954-26-007650.md) | [6.5](/filings/0001654954-25-012910.md) | [6.7](/filings/0001654954-26-007650.md) | [3.7](/filings/0001654954-26-007650.md) | [3.0](/filings/0001654954-26-007650.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,823) d](/filings/0001654954-24-014442.md) | [(2,335) d](/filings/0001654954-25-003443.md) | [(2,509)](/filings/0001654954-25-005746.md) | [(2,425) d](/filings/0001654954-25-009437.md) | [(2,564) d](/filings/0001654954-25-012910.md) | [(3,092) d](/filings/0001654954-26-003094.md) | [(3,494)](/filings/0001654954-26-004903.md) | [(4,127) d](/filings/0001654954-26-007650.md) | [(2,584) d](/filings/0001654954-25-012910.md) | [(4,121) d](/filings/0001654954-26-003094.md) | [(2,508)](/filings/0001654954-26-004903.md) | [211 d](/filings/0001654954-26-007650.md) |
| Capital expenditure | $k | [44.5 d](/filings/0001654954-24-014442.md) | [54.2 d](/filings/0001654954-25-003443.md) | [0.0](/filings/0001654954-25-005746.md) | [46.1 d](/filings/0001654954-24-010673.md) | [28.9 d](/filings/0001654954-24-014442.md) | [480 d](/filings/0001654954-26-003094.md) | [297](/filings/0001654954-26-004903.md) | [15.5 d](/filings/0001654954-26-007650.md) | [457 d](/filings/0001654954-25-012910.md) | [1,128 d](/filings/0001654954-26-003094.md) | [346](/filings/0001654954-26-004903.md) | [907 d](/filings/0001654954-26-007650.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [133](/filings/0001654954-25-005746.md) | [133](/filings/0001654954-25-009437.md) | [133](/filings/0001654954-25-012910.md) | [14.5](/filings/0001654954-26-004903.md) | [14.5](/filings/0001654954-26-007650.md) | [151](/filings/0001654954-25-012910.md) | [17.4](/filings/0001654954-26-004903.md) | [17.6](/filings/0001654954-26-007650.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 17,718,161 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001654954-26-007650.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.